MT-1 vs. MT-2: Which Melanotan Tanning Peptide to Choose and What Is the Difference

A natural tan is the result of a complex biological process controlled by the melanocortin system. When the skin is exposed to ultraviolet light, the body releases alpha-melanocyte-stimulating hormone (α-MSH), which activates receptors on the surface of melanocytes and triggers the synthesis of melanin – the natural photoprotective pigment. The two synthetic peptides MT‑1 (Melanotan I) and MT‑2 (Melanotan II) were created precisely to reproduce and amplify this mechanism, inducing pigmentation without intense sun exposure. Although their names are almost identical, the two molecules differ substantially in structure, receptor selectivity, and profile of action. This article clarifies the differences to help researchers make an informed choice.

1. What is MT‑1 (Melanotan I / Afamelanotide)

MT‑1 (also known as Melanotan I, Afamelanotide, NDP-MSH, [Nle4, D-Phe7]-α-MSH) is a synthetic tridecapeptide – a linear chain of 13 amino acids, an analogue of the natural α-MSH. The two amino acid substitutions (Nle at position 4 and D-Phe at position 7) confer greater potency and stability compared with the natural hormone. In the clinical literature, MT‑1 is described as a selective agonist of the melanocortin-1 receptor (MC1R), i.e. its action is concentrated predominantly on melanogenesis and photoprotection.

An important distinguishing feature of MT‑1 is its clinical history: afamelanotide was studied as a 16 mg controlled-release subcutaneous implant in erythropoietic protoporphyria (EPP) – a rare disease in which patients experience severe pain upon exposure to light. The version offered by Peptology is a lyophilised research peptide with a purity above 99%, confirmed by independent laboratory analysis – this is not a medicinal product, but material intended solely for scientific research and in vitro applications.

2. What is MT‑2 (Melanotan II)

MT‑2 (Melanotan II, MT-II, Melanotan 2 Acetate) is a synthetic cyclic 7-amino-acid peptide with the sequence Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂. Unlike MT‑1, this molecule is a pan-melanocortin agonist – it simultaneously activates the MC1R, MC3R, MC4R, and MC5R receptors. It is precisely this broad activity that explains both its stronger melanogenic effect and its additional effects on libido and appetite, mediated by MC4R.

MT‑2 was developed in the late 1980s at the University of Arizona by the group of Victor J. Hruby and Mac Hadley. The original concept was innovative: to create a synthetic agonist capable of inducing skin darkening without UV exposure, with the potential to prevent skin cancer in high-risk individuals. However, MT‑2 has never undergone a full regulatory programme and remains an unapproved medicinal product in all jurisdictions. Regulators in a number of countries (FDA, UK MHRA, Scandinavian authorities) have issued explicit warnings regarding its unregulated use. In the Peptology catalogue, MT‑2 is offered as a lyophilised research peptide with a purity above 99%, for scientific research purposes only.

3. Mechanism: selectivity versus pan-activity

There are five melanocortin receptors (MC1R–MC5R), and they control different functions – pigmentation (MC1R), steroidogenesis (MC2R), energy balance and libido (MC3R/MC4R). The key difference between the two peptides lies precisely in which of these receptors they bind to:

In other words, both peptides stimulate eumelanin – the brown-black, photoprotective pigment of the skin – but MT‑1 does so with „surgical“ precision, whereas MT‑2 triggers the entire melanocortin system all at once. This selectivity is the reason the purer derivatives were rationally developed from MT‑2: PT‑141 (Bremelanotide) – for libido, and afamelanotide (MT‑1) – for photoprotection.

4. Table: MT‑1 vs MT‑2 – full comparison

The data are for scientific reference and are based on the published literature on afamelanotide and MT‑II. They do not represent a direct head-to-head clinical comparison, nor a claim about the effect of the research-grade product.

5. Similarities between the two peptides

Despite the differences, MT‑1 and MT‑2 share a common origin and a number of characteristics. Both derive from the natural α-MSH and belong to the class of melanocortin agonists. Both stimulate the production of eumelanin and can induce pigmentation without the need for intense UV exposure – although moderate sun exposure enhances the effect of both. Both are administered subcutaneously, are offered as a lyophilised powder with a purity above 99%, and fall into the Peptides for skin, sleep and libido category in the Peptology catalogue. Both require dermatological monitoring of moles and skin lesions because of their effect on pigmentation, and neither is offered as a product approved for human use – both are research peptides.

6. Advantages and disadvantages

7. Which one when: how to choose the right peptide

The choice between the two peptides depends entirely on the objective of the research and on the sensitivity profile:

When MT‑1 is more suitable: when the focus is on pure pigmentation and photoprotection without accompanying central effects. MT‑1 is the logical choice for research in light phototypes (I–II), for models of melanogenesis with a more predictable, gradual profile, as well as when a molecule with a more extensive clinical and scientific record is sought. Because of its weaker effects on libido and appetite, it is the „cleaner“ option when those effects are not desired.

When MT‑2 is more suitable: when a stronger and faster melanogenic effect is sought, or when the research deliberately also covers the MC4R-mediated effects – libido and appetite. MT‑2 is the historical „broad-spectrum“ molecule that covers the entire melanocortin profile in a single compound. It does, however, require more careful dosing and stricter dermatological monitoring.

An important clarification: combining the two peptides is not recommended, since they have a different receptor profile and are usually studied separately. If the primary objective is libido rather than tanning, the more focused choice is PT‑141 (Bremelanotide), which is optimised specifically for MC4R.

8. Safety and melanoma risk

Both peptides affect pigmentation, which makes monitoring of skin lesions a standard precautionary measure. Their safety profiles, however, differ because of the difference in receptor selectivity.

The most critical consideration with MT‑2 is melanoma risk. In the dermatological literature, cases of atypical transformation of moles have been reported in MT‑2 users. A direct causal relationship has not yet been definitively established, but the theoretical mechanism is scientifically plausible. Individuals with a personal or family history of melanoma, with multiple atypical moles, or with a light phototype should avoid MT‑2. This information is a scientific reference and does not constitute instructions for use in humans.

9. Protocol for reconstitution and storage

Both peptides are supplied as a lyophilised powder and require precise reconstitution for reliable experimental results:

• Solvent: use a high-quality stabilising solution – Peptide Matrix Water™ from the Solutions for peptides category is recommended. Inject the liquid slowly down the wall of the vial so as not to disturb the integrity of the lyophilised powder.
• Do not shake: never shake the vial aggressively – foam denatures the peptide. Use gentle swirling motions until fully clear.
• Storage after reconstitution: at 2°C to 8°C – up to 60 days with Peptide Matrix Water™. Avoid direct light and re-freezing. It is recommended that MT‑2 be stored frozen (−20°C) before reconstitution for long-term stability.
• Dose calculation: for precise IU with any given vial and volume, use the peptide reconstitution calculator.

10. Conclusion

MT‑1 and MT‑2 derive from the same hormone and pursue the same ultimate goal – the induction of natural pigmentation – but they achieve it in fundamentally different ways. MT‑1 (Melanotan I) is the selective, clinically studied molecule focused on pure photoprotection and with a more predictable profile, particularly suitable for light phototypes. MT‑2 (Melanotan II) is the original broad-spectrum molecule with a stronger tan, but also with a broader side-effect profile and more serious safety considerations. The right choice depends on the objective of the research, the phototype, and the acceptable risk profile. We at Peptology strive to provide consistent quality for all your research projects in the field of the melanocortin system and pigmentation.